Trial Profile
BGJ398 for the Treatment of Tumor-Induced Osteomalacia
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Infigratinib (Primary)
- Indications Osteomalacia
- Focus Therapeutic Use
- 15 Mar 2021 Status changed from completed to discontinued as study was stopped early due to a greater than expected incidence of ocular AEs and analysis ofthe data from the first 4 subjects indicating that the likelihood of permanent remission withthis therapy was low.
- 05 May 2020 Status changed from active, no longer recruiting to completed.
- 11 Mar 2020 Status changed from recruiting to active, no longer recruiting.